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Abstract
Background: The implication of post-transcriptional regulation by microRNAs in molecular mechanisms underlying
cancer disease is well documented. However, their interference at the cellular level is not fully explored. Functional
in vitro studies are fundamental for the comprehension of their role; nevertheless results are highly dependable on
the adopted cellular model. Next generation small RNA transcriptomic sequencing data of a tumor cell line and
keratinocytes derived from primary culture was generated in order to characterize the microRNA content of these
systems, thus helping in their understanding. Both constitute cell models for functional studies of microRNAs in
head and neck squamous cell carcinoma (HNSCC), a smoking-related cancer. Known microRNAs were quantified
and analyzed in the context of gene regulation. New microRNAs were investigated using similarity and structural
search, ab initio classification, and prediction of the location of mature microRNAs within would-be precursor
sequences. Results were compared with small RNA transcriptomic sequences from HNSCC samples in order to
access the applicability of these cell models for cancer phenotype comprehension and for novel molecule
discovery.
Results: Ten miRNAs represented over 70% of the mature molecules present in each of the cell types. The most
expressed molecules were miR-21, miR-24 and miR-205, Accordingly; miR-21 and miR-205 have been previously
shown to play a role in epithelial cell biology. Although miR-21 has been implicated in cancer development, and
evaluated as a biomarker in HNSCC progression, no significant expression differences were seen between cell types.
We demonstrate that differentially expressed mature miRNAs target cell differentiation and apoptosis related
biological processes, indicating that they might represent, with acceptable accuracy, the genetic context from
which they derive. Most miRNAs identified in the cancer cell line and in keratinocytes were present in tumor
samples and cancer-free samples, respectively, with miR-21, miR-24 and miR-205 still among the most prevalent
molecules at all instances. Thirteen miRNA-like structures, containing reads identified by the deep sequencing, were
predicted from putative miRNA precursor sequences. Strong evidences suggest that one of them could be a new
miRNA. This molecule was mostly expressed in the tumor cell line and HNSCC samples indicating a possible
biological function in cancer.
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Conclusions: Critical biological features of cells must be fully understood before they can be chosen as models for
functional studies. Expression levels of miRNAs relate to cell type and tissue context. This study provides insights on
miRNA content of two cell models used for cancer research. Pathways commonly deregulated in HNSCC might be
targeted by most expressed and also by differentially expressed miRNAs. Results indicate that the use of cell models
for cancer research demands careful assessment of underlying molecular characteristics for proper data interpretation.
Additionally, one new miRNA-like molecule with a potential role in cancer was identified in the cell lines and clinical
samples.
Background
MicroRNAs (miRNAs) are small RNA molecules, typi-
cally between 19 and 22 nucleotides in length, that regu-
late protein-coding genes through sequence-specific
binding to messenger RNAs (mRNAs). These molecules
were first implicated in Caenorhabditis elegans develop-
ment in the early 90s [1], and have been associated with
a variety of biological processes since then [2]. They are
believed to have important roles in cancer aethiology
and progression, and are currently being evaluated for
cancer classification and prognosis [3].
In order to identify cell processes that are affected by
miRNAs, overexpression and inhibition of miRNA genes
are routinely performed for in vitro functional studies.
Well-established cell lines are generally used for this
purpose, since they are readily available from certified
sources that guarantee the genetic identity. Primary cul-
tures, on the other hand, have the advantage of not pre-
senting genetic changes associated with the process of
obtaining immortalized cell lines. It is clear, however,
that experimental data will be biased by the adopted cell
model and should be interpreted with caution.
Head and neck squamous cell carcinoma (HNSCC) is
a smoking-related cancer for which, despite being one of
the most common malignancies worldwide, reliable
diagnostic and prognostic markers are not available [4].
Recent studies have addressed deregulation of micro-
RNAs in the context of HNSCC, suggesting that these
molecules could be used to improve diagnosis and the
outcome of this disease [5].
Cell models are being broadly used in order to compre-
hend the function of specific miRNAs in this disease, but
there is no current information on the miRNA content of
these cells. Due to the complexity of miRNA regulatory
networks, where one miRNA may target multiple genes,
and where a single gene might be targeted by several miR-
NAs, miRNA expression levels (the miRNome) of a cell
line may lead to a significant bias in functional studies
results. Aiming to understand the miRNA background of
cell models used for functional studies in HNSCC, we
report the high-throughput sequencing analysis of the
small RNA transcriptome of an oral squamous cell carcin-
oma cell line (SCC25) and of normal oral keratinocytes
obtained from primary cultures. We believe that a deep
understanding of the molecular background of cell models
should greatly improve knowledge on mechanisms tar-
geted by miRNAs and other gene regulators.
Results
MiRNAs expressed in the carcinoma cell line and in
normal keratinocytes
We aimed to identify miRNAs that are expressed in a hu-
man carcinoma cell line and in a cell type representing its
normal counterpart for miRNA functional studies in the
context of HNSCC. With this purpose we chose SCC25, a
tongue squamous cell carcinoma cell line, and normal oral
keratinocytes derived from primary cultures. Three small
RNA libraries were constructed for each cell type and
sequenced on a SOLiD sequencer. Table 1 shows that,
after filtering out rRNA, tRNA and other contaminants,
2.62% and 3.10% of reads accounted for miRNAs pre-
viously annotated in miRBase (release 18) for SCC25 and
normal keratinocytes, respectively. When we considered
only reads matching mature miRNAs, these numbers
dropped to about 2% in both cases. Three hundred
and thirty one mature miRNAs were identified in
Table 1 Mapping of reads to genome and miRBase v18 after rRNA, tRNA, repeated DNA and adaptor sequences
filtering
SCC25 (million) % Kerat (million) %
Total of reads 3.4 100 4.4 100
Reads matching miRBase V18 0.09 2.64 0.14 3.1
Reads matching mature miRNAs 0.07 2.00 0.9 1.94
Reads mapped to genome and not matching v18 0.13 3.97 0.07 4.53
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keratinocytes and 288 in SCC25, with 202 common miR-
NAs. The complete set of detected mature miRNAs for
both cell types can be found in Additional file 1.
Figure 1 depicts the 10 most represented miRNAs in
SCC25 and keratinocytes. These miRNAs represent 72%
of reads mapping mature miRNAs in keratinocytes and
80% in SCC25. The three most expressed miRNAs were
common to both datasets: miR-21, miR-205 and miR-24.
Both miR-21 and miR-205 have been reported as HNSCC
biomarkers [6], but here there was no differential expres-
sion between the normal cell and the cancer cell line.
Noteworthy is the fact that miR-21 and miR-205 are in-
volved in keratinocyte proliferation and migration [2,7], a
common characteristic that might justify their ubiquous
presence in these epithelium-derived cells. MiR-24, on the
other hand, has not been implicated in HNSCC. A few re-
ports mention a tumor suppressor function for miR-24
through the regulation of apoptosis [8]. We assessed the
expression levels of miR-21 and miR-24 by real-time PCR,
confirming that there was no significant difference in the
expression of the two miRNAs between the two cell types
(data not shown).
Together miR-21, miR-24 and miR-205 may target 66
genes (Additional file 2A). The task of identifying miRNA
gene targets is an essential step for the understanding of
their role in a given cellular environment. However, it is
also a challenging undertaking due to the fact that miR-
NAs are usually imperfectly complementary to the 3′UTR
region of their mRNA targets. Considering these difficul-
ties, in order to access cellular processes targeted by the
three most and commonly expressed miRNAs in the cell
line and the normal keratinocyte, we selected only gene
targets experimentally verified, as reported by miRecords
and TarBase databases. Most of the 66 validated targets
are reportedly involved in cell cycle regulation and pro-
grammed cell death (Additional file 2B). We emphasize
the involvement of these miRNAs in the regulation of
cyclin-dependent kinases (CDKs), key components in cell
cycle regulation and traditional targets for cancer therapy
development, in the regulation of SMAD and of type II
receptor of TGFB (TGFBR2), components of the trans-
forming growth factor beta signaling pathway, as well as
in the regulation of NOTCH1, PI3K and PTEN. A recent
review addresses the relationship between Smad/TGFBR2
Figure 1 Histogram indicating the expression levels of 10 most represented miRNAs in both datasets. (A) 10 most expressed miRNAs in
keratinocytes; (B) 10 most expressed miRNAs in the cell line (SCC25).
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and NOTCH1, PTEN and PI3K, considered relatively new
players in HNSCC [9].
Only seven miRNAs were detected uniquely in keratino-
cytes, when a read count of at least ten reads was consi-
dered: miR-4500, miR-154, miR-337, miR-493, miR-326,
miR-369, miR-381 and miR-627. Only one miRNA was
uniquely expressed in SCC25 with this cut-off: miR-615.
To our knowledge, no targets have been validated for
these molecules up to now.
Differential regulation of miRNAs between the cancer cell
line and normal keratinocytes
The relative abundance of miRNAs was then compared
between the carcinoma cell line and normal keratinocytes.
Among the 202 miRNAs expressed in both cell types, 65
miRNAs were overexpressed in keratinocytes and 42 in
SCC25, when a 2-fold change in expression was consi-
dered. This result is in agreement with previous findings
reporting overall lower levels of miRNAs in cancer as
compared to normal tissues. Twenty miRNAs presenting
higher fold-changes are depicted in Figure 2, where blue
bars correspond to miRNAs mostly expressed in keratino-
cytes and white bars correspond to miRNAs mostly
expressed in the cell line. Additional file 3 summarizes dif-
ferences in gene expression for 107 miRNAs expressed
with a 2-fold change between keratinocytes and the cell
line.
From the 107 miRNAs, we found experimentally vali-
dated targets for only 6 molecules – miR-1, miR-125b and
miR-133a up-regulated in keratinocytes and miR-196a,
miR-511 and miR-7 up-regulated in the cell line. Among
these, we chose to confirm by real time PCR the deregula-
tion of the miRNAs presenting the lowest level of dere-
gulation – miR-1 and miR-133a, up-regulated ~ 2-fold in
keratinocytes, and of miR-196a, up-regulated ~ 2 fold in
the cell line. Results between real time PCR and sequen-
cing were consistent (data not shown). These 6 miRNAs
may target 315 gene targets (Additional file 4A). Pro-
grammed cell death-related genes were the most repre-
sented among targeted genes, mostly grouped under the
GO term Regulation of Apoptosis (GO:0042981, FDR cor-
rected p value < 0.05) (Additional file 4B). This result in-
dicates differences in apoptosis regulation between the
cancer cell line and the normal counterpart. Illustrating
the importance of this scenario for HNSCC, p53, a key
tumor suppressor frequently mutated in HNSCC [10] is
a validated target of miR-125b [11], and this miRNA
has also been recently implicated in the carcinogenesis of
squamous cell carcinomas [12].
Cell differentiation-related genes, grouped under
GO term Positive Regulation of Cell Differentiation
(GO:0045598, FDR corrected p value < 0.05), were also
enriched in the dataset (Additional file 4B), an expected
result considering intrinsic differences between a cell line
and a keratinocyte derived from primary cultures, the later
retaining its full capacity for cell differentiation.
Top over-expressed miRNAs in keratinocytes included
miR-409, reportedly a tumor suppressor in gastric can-
cer [13], miR-3545, a recently described miRNA corre-
sponding to the antisense strand of miR-203, which is a
miRNA preferentially expressed in the skin, and which
has been described as a tumor suppressor molecule si-
lenced in different malignancies [14,15], and miR-376c,
shown to induce apoptosis and described as down regu-
lated in HNSCC [16].
MiR-495 and miR-379 have not been previously asso-
ciated with HNSCC biology or epithelial differentiation,
but miR-495 has been reported to be a tumor suppressor
[17] and miR-379 has been shown to be down-regulated
in HPV positive HNSCC samples [18].
Figure 2 Twenty most differentially expressed miRNAs between keratinocytes and SCC25. The expression level of miRNAs mostly
expressed in keratinocytes is represented in blue and in white is the expression of those more expressed in the cell line.
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Among top over-expressed miRNAs in SCC25, miR-
210 and miR-181c have been previously associated with
HNSCC. MiR-210 has been described as a marker for
tumor hypoxia and a prognostic factor in HNSCC [19].
MiR-181c, reported as up-regulated in tongue squamous
cell carcinoma (TSCC), was the second most up-regulated
miRNA in SCC25 [20].
Taken together these results highlight important diffe-
rences between a cancer cell line derived from the oral
cavity, and its normal counterpart, a keratinocyte de-
rived from a primary culture. These differences are con-
sistent with the genetic background they represent and
should be taken into consideration when cell models are
chosen.
mRNA expression patterns in the cell line and
keratinocytes
DNA microarrays were used in order to evaluate gene
expression differences between keratinocytes and the
cancer cell line that might support processes targeted by
the differential miRNA expression. Even though miR-
NAs are mostly posttranscriptional regulators and their
effect on mRNA abundance would be small in our cell
models, we aimed to access differentially regulated bio-
logical processes and, when possible, associate these dif-
ferences with miRNA regulation potential. A total of 978
genes were over-expressed in SCC25 when a 2-fold dif-
ference in gene expression was considered, while 523
were down-regulated (FDR adjusted p value of 0.05)
(Additional file 5).
Gene Ontology term enrichment analysis of the dif-
ferentially expressed genes dataset identified processes
associated with cell cycle regulation (cell cycle progres-
sion, chromosome segregation and DNA replication)
enriched when genes up-regulated in SCC25 were con-
sidered (Additional file 6A). Genes up-regulated in
keratinocytes were mostly involved with epithelium deve-
lopment (Additional file 6B). These results are mostly
in agreement with expected differences between the cell
types, since up-regulation of proliferation-related pro-
cesses should be a characteristic of a cancer cell line and
epithelium development of a normal keratinocyte.
We then looked for gene targets for the 7 miRNAs that
possess experimentally validated targets addressed in the
previous section – miR-1, miR-133a and miR-125b up-
regulated in keratinocytes and miR-196a, miR-511 and
miR-7 up-regulated in the cell line – in the dataset of
deregulated mRNAs. A total of 21 targets were found
among deregulated genes (Table 2). However, only eight
of these targets presented expression levels inversely cor-
related with the related miRNA, an indication of regula-
tion. Although the correlation of expression levels does
not confirm the regulation of targets by a miRNA, nor
does the lack of gene expression differences indicate that
the targets are not being regulated - since regulation
might not be at the gene expression level and we did not
check protein levels - we chose to present only targets
previously shown to be regulated at the gene expression
level.
Identification of miRNA-like molecules
For the identification of novel miRNA-like molecules, all
reads shorter that 35 nt, having more than 10 copies in
our libraries and no match to known miRNAs were tested.
Reads were mapped to the genome and, at each genomic
locus of a read to be tested, one longer sequence covering
the read was extracted for secondary structure analysis.
This sequence extended 100 nt upstream and 100 nt
downstream from the read and this length was established
following the average length of known human precursor
miRNAs (Additional file 7). A set of 448 sequences
obtained this way was submitted to a four-step annota-
tion procedure: (i) sequence similarity search with the
BLAST program against a locally curated ncRNA data-
base; (ii) structural search against all RFAM families
using INFERNAL, (iii) ab initio characterization using
Table 2 Deregulated miRNA targets in dataset comparing
mRNA expression between the cell line and keratinocytes
Gene target Up-regulated in
cell line
Up-regulated in
Keratinocyte
Related
miRNA
ADAR 3.6 miR-1
ANKRD29 4.1 miR-1
ANP32B 3.4 miR-1
ATP6V1B2 2 miR-1
CDCP1 2.3 miR-1
EPB41L4B 4.3 miR-1
FSTL1 4.7 miR-1
KCNQ1 8 miR-1
POLA2 2.9 miR-1
PREX1 12 miR-1
SSNA1 2.6 miR-1
UST 4.6 miR-1
CDK9 2.3 miR-1
B3GALT4 2.7 miR-125
BMF 31 miR-125
CDKN2A 21 miR-125
IGFBP3 700 miR-125
RHOA 2.3 miR-133a
SET 2.5 miR-196a
SPRR2C 71 miR-196a
SNCA 5 miR-7
The table reports 21 validated gene targets presenting deregulation between
SCC25 and keratinocytes. Fold-change in bold-type indicates that the
fold-change is in agreement with the expression level of the regulator miRNA
in the cell.
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RNAfold and HHMMiR; (iv) manual curation of the re-
sults (Figure 3). Candidates that mapped to known cod-
ing regions were discarded. Of the 448 sequences, 13
presented some evidence in at least one of the proce-
dures. The results are shown in Table 3.
Four candidates presented good BLAST alignments with
sequences in ncRNA databases (Cand7, Cand8, Cand9
and Cand12) and, of these one aligned with a ncRNA
classified as miRNA (Cand8). Three candidates (Cand4,
Cand9 and Cand10) presented good structural alignments
to RFAM families, but of these only two alignments
included the corresponding original reads (candidates
Cand4 and Cand9) and only two candidates aligned to
RFAM families that included mammalian sequences
(Cand9 and Cand10). All candidates but for Cand8 and
Cand10 were predicted by HHMMiR as including miR-
NAs, however only candidates Cand3, Cand4, Cand9,
Cand11 and Cand12 had the original reads included in
predicted stems (Additional file 8).
Five of the thirteen candidates showed evidence of the ori-
ginal read mapping (totally or partially) in a predicted stem
in the precursor sequence considered (Additional file 8).
These full sequences (reads plus extensions constituting pu-
tative precursors) were analyzed with the computational
tool MatureBayes for the identification of possible mature
sequences. As depicted in the Additional file 9, the algo-
rithm did not find a potential functional part in the pro-
posed precursor sequences (putative mature miRNAs) that
contained the original read. This analysis underlines difficul-
ties in novel miRNA discovery, showing that different ap-
proaches are needed for complementarity.
Comparison of results in cells with clinical samples
In order to compare miRNAs expressed in cell cultures
with clinical samples, small RNA libraries from eight
HNSCC patients were constructed and sequenced, fol-
lowing the same procedures described for the cells
(results in Additional file 10). In each case we sequenced
a tumor sample and surgical margins, the later repre-
senting cancer-free tissue. A PCA plot illustrates global
characteristics of these samples: despite heterogeneity
within the two groups, the expression level of shared
molecules is able to differentiate cancer from cancer-free
samples (Figure 4). Table 4 shows that similarities in
miRNA population, when cancer samples were com-
pared to their cell model counterpart, varied from 46%
to about 70%. Since these percentages did not correlate
with the sequencing coverage obtained in this study, we
Figure 3 Workflow for the analysis of small RNA transcriptome focusing on miRNA identification and discovery. Each library was
converted to FASTA format, subjected to RNA2MAP tool and reads that did not match the human genome were discarded. After the filtering
protocol, that matched miRBase were submitted to differential expression analysis and those that did not match were mapped to the genome.
At each genomic locus the read was extended by100 nt up and downstream. Resulting sequences were subjected to the following pipeline:
secondary structure prediction using RNAfold and Infernal against RFAM, blast against a local non-coding RNA database and, ab intio
characterization using HHMMiR and RNAFold (HHMMiR in fact is performed using the data produced by RNAfold).
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Table 3 Putative miRNAs identified using similarity search, structural search and ab initio prediction
Cell line count
(normalized)
Blast search against
miRNAs in local DB1
HHMMR RNAfold Rfam/INFERNAL2
Candidate
number
Genomic
location
Kerat SCC5 score Original read
overlaps Helix?
Keal/mol Family ID Strand Bit score Start End Original reads
overlaps Helix?
1 Intergenic 3.9 9.6 - 0.67 No −72,10 - - - - - - -
2 Intergenic 46 82.5 - 0.69 No −64,49 - - - - - - -
3 Intron 4.4 - 0.69 Partially −51,30 - - - - - - -
4 Intergenic 3.9 51.6 - 0.66 Partially −44,30 MIR245 RF00816 + 29.76 97 182 Total
5 Intron - 8 - 0.7 No 53,52 - - - - - - -
6 Intergenic - 4.8 - 0.66 No −48,90 - - - - - - -
7 Intergenic - 78.9 Original DB: smiRNAdb;
Type: unclassified RNA
QueryCov: 13%;
SbjCov: 97% Id: 100%
0.66 No −57,34 - - - - - - -
8 Intron - 5.6 Origianl DB: smiRNAdb;
Type: miRNA; QueryCov:
11%; SbjCov: 96% Id: 100%
- - 57,10 - - - - - - -
9 Intergenic - 11.2 Original DB: smiRNAdb;
Type: unclassified RNA;
QueryCov: 13%;
SubjectCov: 94%; Id: 100%;
0.67 Total −35,35 mir-450 RF00708 + 30.4 32 112 Parcial
mir-245 RF00816 + 29.76 35 120 Parcial
10 Intergenic - 4.8 - - - −122,82 mir-689 RF00871 + 66.15 17 91 No
11 Intron - 4.8 - 0.66 Total −83,69 - - - - - - -
12 Intron - 4.0 Original DB: smiRNAdb;
Type: unclassified RNA;
QueryCov: 12%;
SubjectCov: 100%: Id: 100%
0.68 Total −50,30 - - - - - - -
13 Intron - 15.2 - 0.67 No −94,14 - - - - - - -
Notation: Original DB: Database from which sequence was downloaded into local database: Type: RNA type (misRNA if not specified); Query Cov: percentage of database sequence covered in the alignment;
Subject Cov: percentage of candidate covered by the alignment; Id: alignment identity; 1: local miRNA database with sequences from databases designated by the Non-coding RNA Databases Resource (NRDR).
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concluded that sequencing depth for each clinical sam-
ple was adequate.
Despite differences in absolute quantities, miRNAs
highlighted as most expressed in cells are frequently
present among the most expressed miRNAs in clinical
samples (Figure 5). Noteworthy is again the widespread
expression of miR-21, miR-24 and miR-205, already ad-
dressed in cells. This result corroborates the assumption
that these abundant molecules are involved in processes
common to epithelial cells and/or maintenance, and do
not seem to be affected by the cancer phenotype.
On the other hand, the scenario describing the dif-
ferential expression between cancer samples vs cancer-
free tissue is more complex and not directly comparable
with results obtained for cell lines. This is expected due
to the complexity of the addressed tumor type. For
instance, miR-409, presenting the highest fold-change
between the keratinocytes and the cancer cell line was
over-expressed in cancer-free tissue in only four patients,
while miR-210, highly over-expressed in the cell line when
compared to keratinocytes, was not differentially ex-
pressed in our clinical samples. In Additional file 11 we
show the comparisons between common miRNAs in
cancer and cancer-free tissue and their cell counterpart.
Finally, we considered the expression levels in the
genomic region containing the miRNA candidate pro-
posed in this study. Table 5 depicts the expression of the
two reads that constitute the candidate in each clinical
Figure 4 Unsupervised classification by principal components analysis of cancer and cancer-free samples. Principal components analysis
(PCA) was used to classify 15 samples (8 cancer samples and 7 cancer-free samples) based on the expression profile of 193 miRNAs expressed in
all samples. Sample 306 M was not included in this analysis due to its high heterogeneity. The PCA plot depicts 70% of variability in the dataset.
Table 4 Common miRNAs identified in cells and clinical
samples.
Sample Total of
miRNAs
Common
miRNAs
% of common miRNAs with
related cell type
196 M 313 219 69.97
196 T 279 178 63.80
240 M 321 223 69.47
240 T 298 184 61.74
277 M 558 294 52.69
277 T 335 187 55.82
296 M 642 309 48.13
296 T 393 212 53.94
306 M 589 286 48.56
306 T 641 269 41.97
321 M 495 273 55.15
321 T 515 243 47.18
333 M 350 240 68.57
333 T 503 246 48.91
349 M 585 292 49.91
349 T 480 221 46.04
Tumor samples were compared to the cancer cell line and tumor-free samples
with normal keratinocytes.
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sample. Samples 196, 306, 312, and 333 showed similar
levels of expression found in cells. Results suggest that
the molecule might be functional and have a role in
HNSCC.
Discussion
Complex regulatory networks connect genes within cel-
lular processes. MiRNAs have been recently added to
this scenario, constituting an additional layer in gene
regulation. The involvement of miRNAs in fundamental
biological processes such as cell differentiation and
programmed cell death, as well as their implication in
innumerous human diseases, are currently known. The
comprehension of their roles at a systems-level, how-
ever, is far from complete.
Once a miRNA is identified as a player in a patho-
logical condition, functional studies using cell models
are commonly used to address its involvement in gene
regulation and consequent phenotypes. Due to the com-
plex interactions between miRNAs and gene targets, the
knowledge regarding the expression of miRNAs in
available cell models should be carefully considered be-
fore tackling miRNA functional assays. Additionally, the
response of cell lines to different stimuli varies due to,
among other issues, their particular genetic background.
For squamous cell carcinoma cell lines, distinct patterns
of proliferation and survival upon treatment with drugs or
environmental stress have been reported in the literature
[21-23]. Regulation of miRNAs certainly impacts these
conclusions, even though it was not addressed in the
above-mentioned studies.
In this study we addressed the miRNA constitution of
a cancer cell line and normal oral keratinocytes, both
used as models for head and neck squamous cell carcin-
oma and its cancer-free counterpart, respectively. Our
results comparing the expression of miRNAs expressed
in both cell types corroborate literature findings. For
instance, the expression of miR-205 was comparable in
both cell types, in agreement with its description as a
marker of squamous epithelia [6], and higher expression
levels of miR-125b in keratinocytes corroborates re-
cently published data implicating the loss of miR-125
Figure 5 Most expressed miRNAs in keratinocytes, cell line and in clinical samples. A: Most expressed miRNAs in keratinocytes (Krt) and in
tumor-free samples; B: Most expressed miRNAs in the cancer cell line (SCC25) and in tumor samples. MiRNAs are reported in alphabetical and
numerical order. The presence of a given miRNA in the dataset is indicated by gray color.
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and HNSCC carcinogenesis [12]. On the other hand,
unexpected results such as the finding of miR-21 equally
expressed between the cell models, a miRNA commonly
deregulated in cancer [24], was confirmed by differences
in the expression level of this miRNA found between
our clinical samples.
Through the relationship between miRNA expression
levels and the targets they could be regulating we show
that important cancer hallmarks i.e. cell death and cell
proliferation regulation, could be intensely affected by
the expression of these molecules. On the other hand, we
also demonstrate that the expression of certain miRNAs,
and, consequently, processes they target, might be
independent of the cancer phenotype. For this result we
addressed miRNAs that did not show differences in ex-
pression between the cell types and their experimentally
validated gene targets reported in the literature. As ex-
pected, expression levels of miRNAs in clinical samples
varied and did not always correlate with findings in the
cell models.
We have also performed an in silico analysis to search
for new miRNA candidates. It is currently known that
high throughput sequencing technologies allow for the
discovery of novel molecules, due to their inherent sen-
sibility and accuracy. The analysis used structural align-
ment against known miRNA families, ab initio prediction
using HHMMiR and RNAfold, and similarity search
against a curated miRNA local database. Since we were
sequencing small RNAs, we postulated that any miRNA
sequenced in the process was a mature miRNA, and
therefore had to be part of a stem in the precursor miRNA
secondary structure. Of the 13 candidates with any
miRNA evidence, in only five there was any evidence that
the original read mapped totally or partially in a predicted
stem (Cand03, Cand04, Cand09, Cand11, Cand12), these
will be discussed in detail. Cand3 had only a HHMMiR
prediction, which partially included the original sequence
in a stem, and was expressed only in keratinocytes.
Cand11 presented a good HHMMiR prediction, and was
expressed only in SCC25 cells. Cand12, had evidence
coming from a HHMMIR positive prediction and an
alignment against an uncharacterized small ncRNA in
smiRNAdb. Cand4 had a positive HHMMiR prediction
and an alignment to a known miRNA family (RF00816).
Cand9 also mapped to the same RFAM family (RF00816),
with the original read located in a predicted stem. In fact,
the genomic mapping of the candidates showed that they
Cand4 and Cand9 correspond to adjacent genomic loca-
tions (Figure 6). The original reads of each candidate
covered both sides of the same predicted stem in the
miRNA family. Additionally both candidates were more
expressed in SCC25 cells when compared to keratinocytes
(51.6 vs 3.9 for Cand4, 11.2 vs. 0 for Cand9). A close
investigation of the RF00816 family in RFAM shows
miRNAs have been characterized for 14 different species
(6 species of nematodes and 8 species or arthropods).
Finally Cand9 had a hit against an undefined small ncRNA
deposited in the smiRNAdb database. Cand9 also had a
structural alignment to the RFAM family RF00708, but
this alignment included only 12 bases of the original read,
and in spite of the fact that the family has been characte-
rized in human, the alignment did not cover the whole
consensus sequence.
All candidates were also submitted to the software
MatureBayes, which identifies mature sequences within
putative precursors, but in none of the candidates the
Table 5 Expression of Cand4 and Cand9 (reads from
predicted miRNA) in clinical samples
Sample 196 Read count (Raw) Normalized read count
196 M 196 T 196 M 196 T
Cand99 159 129 41.19 63.66
Cand209 4 1 1.04 1.60
Sample 240 Read Count (Raw) Normalized Read Count
240 M 240 T 240 M 240 T
Cand99 1076 26 278.77 10.41
Cand209 40 - 10.36 -
Sample 277 Read Count (Raw) Normalized Read Count
277 M 277 T 277 M 277 T
Cand99 391 16 101.30 6.41
Cand209 8 15 2.07 6.01
Sample 296 Read Count (Raw) Normalized Read Count
296 M 296 T 296 M 296 T
Cand99 1566 335 405.72 134.13
Cand209 9 10 2.33 4.00
Sample 306 Read Count (Raw) Normalized Read Count
306 M 306 T 306 M 306 T
Cand99 222 166 57.52 66.46
Cand209 2 3 0.52 1.20
Sample 321 Read Count (Raw) Normalized Read Count
321 M 321 T 321 M 321 T
Cand99 86 170 22.28 68.06
Cand209 - 1 - 0.40
Sample 333 Read Count (Raw) Normalized Read Count
333 M 333 T 333 M 333 T
Cand99 164 985 42.49 394.38
Cand209 - 3 - 1.20
Sample 349 Read Count (Raw) Normalized Read Count
349 M 349 T 349 M 349 T
Cand99 177 50 45.86 20.02
Cand209 - 1 - 0.40
Samples 196, 306, 321 and 333 presented expression levels similar to findings
in cells.
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original read was considered as a mature miRNA. How-
ever, in this software, the definition of the precursor
sequence could significantly impact the results. Our pu-
tative precursor sequences were based on the average
length of precursors in humans. The extension of 100nt
on both sides of the read derives from the fact that we
did not have enough information to the position the
read within its precursor. This may have affected the
quality of the software’s predictions.
This conjunction of evidences point to the genomic
region comprising candidates Cand4 and Cand9 as a
strong candidate for a new miRNA gene. Other two can-
didates, Cand11 and Cand12, also presented consistent
evidence, but based only on HMMIR, which is heavily
dependent on the folding provided by the RNAfold
algorithm, and suffers from the same dependence of the
putative precursor sequence as MatureBayes.
The genomic region comprising the strongest candi-
date for a new miRNA was evaluated in clinical samples.
Expression levels of the sequences that originated Cand4
and Cand9 were up-regulated in several tumor samples,
when compared to cancer-free surgical margins, sug-
gesting that this molecule might, indeed, have a role in
HNSCC. Further experiments are necessary in order to
confirm if the molecule is truly a miRNA.
Conclusions
MiRNA content of two cell models used for HNSCC
cancer research was characterized by deep sequencing.
Several miRNAs were equally expressed between a
cancer cell line and keratinocytes, suggesting that the
regulation of processes targeted by these molecules may
be independent from the cancer phenotype. On the
other hand, we provide evidences that pathways com-
monly deregulated in HNSCC, such as apoptosis and cell
differentiation, may be targeted by miRNAs differentially
expressed between cell types. Our results also imply that
the use of cell models for microRNA functional studies in
cancer research demands careful assessment of underlying
molecular characteristics for proper data interpretation.
The characterization of putative novel microRNA mole-
cules carried out here revealed one strong new miRNA
gene to be experimentally validated. This candidate was
mostly expressed in the cancer cell line and its expression
was validated in clinical samples, indicating a possible role
in cancer.
Figure 6 Structural alignment of candidates Cand4 and Cand9 against RFAM family RF00816. A: Secondary structure of family RF00816
and regions corresponding to the original reads of candidates Cand4 and Cand9; B: INFERNAL alignment of candidates Cand4 and Cand9 against
family RF00816 - the original reads correspond to positions 100–130 of each candidate.
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Methods
Cell culture
We used the HNSCC cell line SCC25, derived from a SCC
of the tongue for small RNA transcriptome sequencing. It
was obtained from the American Type Culture Collection
(ATCC catalog number CRL-1628). For the purpose of this
study, the cell line was grown in a Dulbecco’s Modified
Eagle’s medium/Nutrient Mixture F-12 Ham (DMEM/
F12) supplemented with 10% fetal bovine serum in a hu-
midified atmosphere of 5% CO2 and 95% air at 37°C.
Human oral epithelial tissue was obtained from healthy
volunteers undergoing dental surgeries, following previously
published procedures [6], after approval by the Research
Ethics Committee of IPEN under License Number 087/
CEP-IPEN/SP and with informed consent signature. Kera-
tinocytes used for small RNA transcriptome sequencing
and gain-of-function experiments were grown on a fibro-
blast feeder-layer in a Dulbecco’s Modified Eagle Medium
(DMEM; Gibco, New York, NY, USA) F-12 Nutrient
Mixture (HAM, Gibco, New York, NY, USA) (2:1), with
10% Bovine Serum Product Fetal Clone III (Hyclone,
Logan, Utah, USA), penicillin (100 U/ml), streptomycin
(100 lg/ml), gentamicin (50 lg/ml), and amphotericin B
(2.5 lg/ml) glutamine (4 mM), adenine (0.18 mM)
(Sigma–Aldrich, St. Louis, MO, USA), insulin (5 lg/ml)
(Sigma–Aldrich, St Louis, MO, USA), hydrocortisone
(0.4 lg/ml) (Sigma–Aldrich, St Louis, MO, USA), cholera
toxin (0.1 nM) (Sigma–Aldrich, St Louis, MO, USA), triio-
dotyronine (20 pM) (Sigma–Aldrich, St Louis, MO, USA)
and epidermal growth factor (10 ng/ml) (R&D Systems,
Minneapolis, MN, USA).
Clinical samples
Eight patients with oral squamous cell carcinoma
(tongue and floor of the mouth) were selected for this
study. The clinical and pathological profile of patients is
shown in Table 6. Tumor and corresponding cancer free
surgical margins containing the corresponding epithe-
lium were collected from patients submitted to surgical
resection of primary tumor at Hospital das Clinicas,
Hospital Heliopolis and Arnaldo Vieira de Carvalho
Cancer Institute, in Sao Paulo, Brazil. All patients pro-
vided written informed consent, and the research protocol
was approved by review boards of all institutions involved
and by the National Committee of Ethics in Research
(CONEP 1763/05). Samples were snap-frozen in liquid ni-
trogen immediately after surgery. Analysis of hematoxylin
and eosin-stained sections confirmed that >75% tumor
cells in all HNSCC samples and that surgical margins
were tumor-free.
Small RNA library construction and sequencing
Total RNA was obtained from confluent cell cultures or
clinical samples using the mirVana Isolation Kit (Ambion
Inc., USA). The concentration and quality were deter-
mined using a Nanovue spectrophotometer (GE Health-
care). Library construction followed, strictly, the SOLiD
Total RNA-Seq Kit for Small RNA Libraries protocols
(Ambion Inc., USA). Three libraries were constructed for
each cell type. Eight hundred ng of total RNA were used
as a template to obtain the small RNA library and we used
the SOLiD RNA Barcoding System (Ambion Inc., USA)
for library multiplexing. The SOLiD3 sequencing system
(Life Technologies, CA, USA) was used to generate reads
that were 35 bp long. Default parameters were used at all
instances during sequencing.
Sequencing data analysis
Sequence analysis was performed using the Small RNA
Analysis Tool (RNA2MAP) [25] using the following pa-
rameters: three color-space mismatches within the ‘seed
sequence’ (first 18 bases of the reads), and six color-space
mismatches on the following positions of the 35 bp reads.
All sequences that matched tRNA, rRNA, DNA repeats
and adaptor molecules were filtered out and then the
remaining reads were matched against miRNA precursor
sequences in miRBase release 18. Then, using a Perl script
we selected only reads containing mature sequences.
The RNA2MAP mapping tool generated two types of
alignment: reads uniquely mapped to miRNAs and reads
generating multiple hits. In order to select for molecules
most likely to represent a mature miRNA we restricted
multiple alignments to 5 hits and such hits should be
within variations of a single miRNA family. For instance,
reads mapping identically to hsa-mir-103a-1 and hsa-
mir-103a-2 counted as “hsa-mir-103a”. Reads generating
multiple hits that did not conform to these parameters
were discarded.
Following the identification of miRNAs present in
each sample, we also used Perl scripts to compare nor-
mal keratinocytes and SCC25, and cancer and cancer-
free patients.
To compare the expression data levels, the expression of
each mature miRNA was normalized using the highest
Table 6 Clinical data of patients in this study
Patient Tumor site Gender Age (yr)
196 OC-T Male 49
240 OC-FOM Male 75
277 OC-T Male 66
296 OC-FOM Male 53
306 OC-FOM Female 82
321 OC-FOM Male 69
333 OC-T Male 52
349 OC-FOM Male 59
OC-T: Oral Cavity – Tongue, OC-FOM: Oral Cavity - Floor of the Mouth.
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expression value in the dataset [26] and miRNAs presen-
ting a difference in expression level of at least 2-fold were
considered differentially expressed between datasets.
For data visualization of clinical samples, expression
patterns of miRNA detected in every sample were clus-
tered by Principal Components Analysis (PCA) using
Partek Genomics Suite (v6.6).
The miRNA targets were searched using Ingenuity
Pathway Analysis (http://www.ingenuity.com), through
the integration of Tarbase and miRecords databases. For
pathway mapping and Gene Ontology term enrichment
analysis we used DAVID Bioinformatics Resources
(http://david.abcc.ncifcrf.gov).
Relative quantitation of gene expression by real-time PCR
For miRNA expression analysis, the cDNA was synthe-
sized from 100 ng of total RNA using sequence-specific
stem-loop primers for hsa-miRNA-1, hsa-miRNA-7,
hsa-miRNA-21, hsa-miRNA-24, hsa-miRNA-133, hsa-
miRNA-196 and for the endogenous control RNU48
(TaqMan miRNA RT kit, Life Technologies, Carlsbad,
CA, USA). The relative quantitation of miRNA was car-
ried out using the Taqman Universal PCR Master Mix
(Life Technologies, Carlsbad, CA, USA), according to
the manufacturer’s instructions. Data was normalized to
the expression of RNU48 and analyzed using the delta
delta Ct method.
Microarray analysis
Microarray analysis was performed using Agilent Whole
Human Genome Microarray 4 × 44 K arrays and labeled
using the One Color Quick Amp Labeling Kit (Agilent
Technologies). A total of four samples were analyzed:
two biological replicates of SCC25 and two biological
replicates of normal keratinocytes. Hybridization and
washing followed protocols described by the manu-
facturer (Agilent Technologies). The one-color arrays
were scanned by GenePix 4000B Scanner (Axon), and
analyzed using the Agilent Feature extraction software
(version 9.5). The quality control of the microarrays was
assessed using the standard Agilent controls to verify
that the arrays met the expected criteria. The gPro-
cessedSignal from each array was loaded into Partek
Genomics Suite (v6.6) and normalized between arrays
using quantile normalization. For subsequent statistical
analysis we used the ANOVA implementation of Partek.
Differences between cell lines and between clinical sam-
ples are presented in fold-changes. The raw data can be
assessed at Gene Expression Omnibus under the acces-
sion number GSE41436.
Discovery of novel miRNA
All reads that did not match miRBase v18 were subjected
to a bioinformatics pipeline represented in Figure 3.
Reads were initially clustered based on their genomic
positions and extended by 100 nucleotides upstream
and downstream from their genomic coordinates. The
size of the extension was based on an analysis of the
sizes of known precursor human miRNAs deposited in
miRBase v 16, which revealed that 98% of these miRNAs
had size smaller than 135nt (Additional file 7). Including
most of the hypothetical precursor sequence was im-
portant for the structural characterization of the candi-
dates (INFERNAL, RNAFold and HHMMiR). The 448
sequences extracted in this manner formed a miRNA
candidate set.
All 448 candidate miRNA sequences obtained as des-
cribed above were then submitted to a 5-step analysis:
similarity search against miRNA sequences, false posi-
tive detection, structural search against RFAM, ab initio
classification using HHMMiR, folding using RNAfold
(version 1.8) and tabulation of the results.
Similarity search against known miRNA sequences was
performed against a local miRNA database with sequences
from databases designated by NRDR [27] as containing
miRNAs. Sequences from 15 different databases were
included [28], miRBase [29], miRNAMap [30], microRNA.
org [31], Argonaute, ASRP [32], CSRDB [33], fRNAdb
[34], ncRNAdb [35], NONCODE [36], RFAM [37], RNAdb
[38], smiRNAdb [39], TarBase [40], UCSC Genome
Browser human miRNAs [41]. Similarity search was per-
formed using WU-BLAST v.2.2.6 with the DUST filter
turned on, wordsize 6, and minimum e-value of 0.0001.
Results were filtered to the following cutoff values: mini-
mum 80% coverage of the query or of the subject se-
quence, 80% minimum identity. False positive detection
adopted the conservative approach of excluding all candi-
dates mapping on known exons, all candidates that
matched other ncRNA types on our local database and all
candidates postulated as tRNAs by tRNAScan-SE version
1.23 [42].
Structural search against RFAM version 9.1 [37] was
performed using INFERNAL version 0.81 with the rec-
ommended cutoff value 25. Ab initio prediction with
HHMMiR version 1.2 was performed using the recom-
mended cutoff value of 0.71 MLE.
Identification of mature miRNAs within putative
precursors
In order to identify a mature miRNA sequence within
putative miRNA precursors, following the analysis pre-
sented in Figure 3 candidates that showed the original
read mapping to a predicted stem (at least partially)
were analyzed using the MatureBayes algorithm [43].
This computational tool incorporates a Naive Bayes
classifier to identify mature miRNA candidates based on
sequence and secondary structure information of their
miRNA putative precursors.
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Additional files
Additional file 1: Complete set of detected mature miRNAs in the
cancer cell line (SCC25) and in normal keratinocytes.
Additional file 2: (A) Experimentally validated targets for miR-21,
miR-24 and miR-205 and (B) KEGG/Gene Ontology term enrichment
analysis for these genes. Targets were selected using the tool
MicroRNA Target Filter from Ingenuity Pathway Analysis. KEGG and Gene
Ontology term enrichment analysis were performed using DAVID
Bioinformatics Resources (http://david.abcc.ncifcrf.gov/home.jsp).
Additional file 3: Differential microRNA expression between the cell
line and keratinocytes.
Additional file 4: (A) Experimentally validated targets for
microRNAs differentially expressed between keratinocytes and the
cell line and (B) Gene Ontology term enrichment analysis for these
genes. Targets were selected using the tool MicroRNA Target Filter from
Ingenuity Pathway Analysis. Gene Ontology term enrichment analysis was
performed using DAVID Bioinformatics Resources (http://david.abcc.
ncifcrf.gov/home.jsp).
Additional file 5: Differential gene expression (mRNA) between the
cell line and keratinocytes.
Additional file 6: Gene Ontology term enrichment analysis for
differentially expressed genes between the cell line and
keratinocytes. A: Functional analysis of genes up-regulated in SCC25.
B: Functional analysis of genes up-regulated in keratinocytes. Gene
Ontology term enrichment analysis was performed using DAVID
Bioinformatics Resources (http://david.abcc.ncifcrf.gov/home.jsp).
Additional file 7: Average lengths of known human precursor
miRNAs. The bar chart shows the length of precursor human miRNAs
deposited in miRBase v. 16.
Additional file 8: Secondary structures of miRNA putative
precursors as predicted by RNAfold. The structures were predicted
using default parameters of the computational tool. The RNAFold
webserver can be found at http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi.
Additional file 9: Identification of functional parts (mature miRNAs)
within putative precursor sequences using the computational tool
MatureBayes. On the precursor sequences defined in this paper as
possible miRNA candidates we highlight the sequenced read (green),
mature miRNA prediction at the 3’ stem (red) and mature miRNA
prediction at the 5′ stem (blue). The identification of mature sequences
followed the procedures in the site http://mirna.imbb.forth.gr/
MatureBayes.html
Additional file 10: Sequencing results from clinical samples.
Additional file 11: Fold-change between cells (SCC25 vs
keratinocytes) and Clinical Samples (tumor vs tumor-free samples).
Fold-change in blue indicates overexpression in keratinocytes or tumor-
free sample. Fold-change in red indicates overexpression in the cell line
or in tumor sample.
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